PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Anal PharmaPoint-Colorectal Cancer - Global Drug Foreca | Page 2

- The entrance of these agents in the CRC market will intensify the competition in the second- line metastatic setting onwards, which will be worsen by the launch of bevacizumab biosimilars, starting in 2018. Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001740886/sample . Report Scope - Overview of CRC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. - Annualized CRC therapeutics market revenue, cost of therapy, and treatment usage pattern data in 8 patient segments, forecast from 2015 to 2025. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CRC therapeutics market. - Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. - Analysis of the current and future market competition in the global CRC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Inquire for Report at http://www.reportsweb.com/inquiry&RW0001740886/buying . Contact Us: Call: [phone] Email: [email protected]